• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

改进的具有增强交叉保护作用的灭活流感疫苗。

An Improved Inactivated Influenza Vaccine with Enhanced Cross Protection.

机构信息

KJ Biosciences LLC, College Station, TX, United States.

Department of Veterinary Pathobiology, Texas A&M University, College Station, TX, United States.

出版信息

Front Immunol. 2018 Aug 9;9:1815. doi: 10.3389/fimmu.2018.01815. eCollection 2018.

DOI:10.3389/fimmu.2018.01815
PMID:30140267
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6094167/
Abstract

Current inactivated influenza vaccines are strain-specific and poorly effective against variant or mismatched viruses. They are standardized based on their hemagglutinin (HA) or ability to induce strain-specific hemagglutination inhibition (HAI) antibodies. The HA is known to undergo major conformational changes when exposed to the low pH environment of endosomes (pH 5.0 and 37°C), which are required for membrane fusion during virus cell entry. In an effort to improve these vaccines, influenza antigens treated under various low pH conditions were evaluated for increased cross-reactive antibody response and cross protection. It was found that a full range of structural and antigenic changes in HA could be induced by varying low pH treatment conditions from the mild (low pH at ≤25°C) to the strong (low pH at ≥37°C) as determined by analysis of potency, HA morphology, protease sensitivity, and reactivity with an anti-HA2 domain (CD) antibody. Inactivated antigens of both H1N1 and H3N2 strains treated at mild low pH conditions (0-25°C) exhibited only moderate HA structural and antigenic changes and markedly increased antibody response against HA2, the highly conserved part of HA, and cross protection against heterologous challenge in mice by up to 30% in survival. By contrast, antigen treated with low pH at 37°C showed more extensive structural and antigenic changes, and induced much less of an increase in antibody response against HA2, but a greater increase with response against HA1, and did not provide any increased cross protection. These results suggest that the increased response against HA2 obtained with the mild low pH treatment is associated with the increased cross protection. These antigens treated at the mild low pH conditions remained capable of inducing a high level of strain-specific HAI antibodies. Thus, they could readily be formulated as an inactivated influenza vaccine which not only provides the same strain-specific protection but also an increased cross protection against heterologous viruses. Such a vaccine could be particularly beneficial in cases of vaccine mismatch.

摘要

目前的流感灭活疫苗是针对特定毒株的,对变异或不匹配的病毒效果不佳。它们是基于其血凝素(HA)或诱导针对特定毒株的血凝抑制(HAI)抗体的能力来标准化的。已知 HA 在暴露于内体的低 pH 环境(pH5.0 和 37°C)时会发生重大构象变化,这是病毒进入细胞时膜融合所必需的。为了改进这些疫苗,评估了在各种低 pH 条件下处理的流感抗原,以提高交叉反应性抗体反应和交叉保护。研究发现,通过改变从温和(≤25°C 的低 pH)到强烈(≥37°C 的低 pH)的低 pH 处理条件,可以诱导 HA 的全范围结构和抗原变化,这是通过分析效力、HA 形态、蛋白酶敏感性以及与抗 HA2 结构域(CD)抗体的反应性来确定的。在温和低 pH 条件(0-25°C)下处理的 H1N1 和 H3N2 株的灭活抗原仅表现出中度的 HA 结构和抗原变化,并显著增加了对 HA2 的抗体反应,HA2 是 HA 的高度保守部分,对异源挑战的交叉保护提高了 30%,在小鼠中的存活率。相比之下,用低 pH(37°C)处理的抗原表现出更广泛的结构和抗原变化,对 HA2 的抗体反应增加幅度较小,但对 HA1 的抗体反应增加幅度较大,并且没有提供任何增加的交叉保护。这些结果表明,温和低 pH 处理获得的对 HA2 的增加反应与增加的交叉保护有关。这些在温和低 pH 条件下处理的抗原仍然能够诱导高水平的针对特定毒株的 HAI 抗体。因此,它们可以很容易地被制成灭活流感疫苗,不仅提供针对特定毒株的保护,还提供针对异源病毒的增加交叉保护。在疫苗不匹配的情况下,这种疫苗尤其有益。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15a8/6094167/4f3a99e70cf3/fimmu-09-01815-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15a8/6094167/4b99877dba7a/fimmu-09-01815-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15a8/6094167/4ce7e5f5e91a/fimmu-09-01815-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15a8/6094167/f3116ff20932/fimmu-09-01815-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15a8/6094167/5ff3dc2951c6/fimmu-09-01815-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15a8/6094167/8cb953c6fa3e/fimmu-09-01815-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15a8/6094167/321850cd6ad0/fimmu-09-01815-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15a8/6094167/df7588abe996/fimmu-09-01815-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15a8/6094167/4f3a99e70cf3/fimmu-09-01815-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15a8/6094167/4b99877dba7a/fimmu-09-01815-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15a8/6094167/4ce7e5f5e91a/fimmu-09-01815-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15a8/6094167/f3116ff20932/fimmu-09-01815-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15a8/6094167/5ff3dc2951c6/fimmu-09-01815-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15a8/6094167/8cb953c6fa3e/fimmu-09-01815-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15a8/6094167/321850cd6ad0/fimmu-09-01815-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15a8/6094167/df7588abe996/fimmu-09-01815-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15a8/6094167/4f3a99e70cf3/fimmu-09-01815-g008.jpg

相似文献

1
An Improved Inactivated Influenza Vaccine with Enhanced Cross Protection.改进的具有增强交叉保护作用的灭活流感疫苗。
Front Immunol. 2018 Aug 9;9:1815. doi: 10.3389/fimmu.2018.01815. eCollection 2018.
2
Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.灭活H7流感病毒疫苗尽管仅诱导产生低水平的中和抗体,但仍可保护小鼠。
J Virol. 2017 Sep 27;91(20). doi: 10.1128/JVI.01202-17. Print 2017 Oct 15.
3
Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for Protection in a Serum Transfer Mouse Challenge Model.人血清中流感病毒血凝素茎特异性抗体是血清转移小鼠攻毒模型中保护作用的替代标志物。
mBio. 2017 Sep 19;8(5):e01463-17. doi: 10.1128/mBio.01463-17.
4
Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.神经氨酸酶抑制抗体滴度与对同一神经氨酸酶亚型的异源流感病毒株的保护作用相关。
J Virol. 2018 Aug 16;92(17). doi: 10.1128/JVI.01006-18. Print 2018 Sep 1.
5
Egg-based influenza split virus vaccine with monoglycosylation induces cross-strain protection against influenza virus infections.以鸡蛋为基础的单糖基化流感裂病毒疫苗可诱导针对流感病毒感染的跨株保护。
Proc Natl Acad Sci U S A. 2019 Mar 5;116(10):4200-4205. doi: 10.1073/pnas.1819197116. Epub 2019 Feb 19.
6
Vaccination with 2014-15 Seasonal Inactivated Influenza Vaccine Elicits Cross-Reactive Anti-HA Antibodies with Strong ADCC Against Antigenically Drifted Circulating H3N2 Virus in Humans.接种2014 - 15季节性灭活流感疫苗可诱导产生交叉反应性抗血凝素抗体,对人体中发生抗原漂移的流行H3N2病毒具有强大的抗体依赖的细胞介导的细胞毒性作用。
Viral Immunol. 2016 May;29(4):259-62. doi: 10.1089/vim.2016.0003. Epub 2016 Mar 7.
7
Monoclonal Antibody Responses after Recombinant Hemagglutinin Vaccine versus Subunit Inactivated Influenza Virus Vaccine: a Comparative Study.重组血凝素疫苗与亚单位灭活流感病毒疫苗接种后的单克隆抗体反应:一项比较研究。
J Virol. 2019 Oct 15;93(21). doi: 10.1128/JVI.01150-19. Print 2019 Nov 1.
8
Evaluation of the Immune Responses to and Cross-Protective Efficacy of Eurasian H7 Avian Influenza Viruses.欧亚H7禽流感病毒免疫反应及交叉保护效力评估
J Virol. 2017 May 12;91(11). doi: 10.1128/JVI.02259-16. Print 2017 Jun 1.
9
A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses.一种二价异源DNA病毒样颗粒初免-加强疫苗可引发针对1型和2型甲型流感病毒的广泛保护。
J Virol. 2017 Apr 13;91(9). doi: 10.1128/JVI.02052-16. Print 2017 May 1.
10
Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity.诱导针对流感的异亚型交叉保护作用的全灭活病毒疫苗:病毒膜融合活性的作用。
PLoS One. 2012;7(1):e30898. doi: 10.1371/journal.pone.0030898. Epub 2012 Jan 27.

引用本文的文献

1
Inactivated recombinant influenza vaccine: the promising direction for the next generation of influenza vaccine.灭活重组流感疫苗:下一代流感疫苗的有前途方向。
Expert Rev Vaccines. 2024 Jan-Dec;23(1):409-418. doi: 10.1080/14760584.2024.2333338. Epub 2024 Mar 25.
2
Preclinical immunogenicity assessment of a cell-based inactivated whole-virion H5N1 influenza vaccine.基于细胞的灭活全病毒H5N1流感疫苗的临床前免疫原性评估。
Open Life Sci. 2022 Sep 26;17(1):1282-1295. doi: 10.1515/biol-2022-0478. eCollection 2022.
3
Inhibition of H1 and H5 Influenza A Virus Entry by Diverse Macrocyclic Peptides Targeting the Hemagglutinin Stem Region.

本文引用的文献

1
A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases.通用流感疫苗:美国国立过敏和传染病研究所的战略计划。
J Infect Dis. 2018 Jul 2;218(3):347-354. doi: 10.1093/infdis/jiy103.
2
Development of a novel dual-domain nanoparticle antigen construct for universal influenza vaccine.新型双域纳米颗粒抗原构建物用于通用流感疫苗的研发。
Vaccine. 2017 Dec 15;35(50):7026-7032. doi: 10.1016/j.vaccine.2017.10.051. Epub 2017 Nov 6.
3
The Pathway to a Universal Influenza Vaccine.通向通用流感疫苗之路。
多种靶向血凝素茎区的大环肽抑制 H1 和 H5 型流感病毒进入。
ACS Chem Biol. 2022 Sep 16;17(9):2425-2436. doi: 10.1021/acschembio.2c00040. Epub 2022 Aug 4.
4
Pregnancy and Birth Outcomes during the Early Months of the COVID-19 Pandemic: The MOACC-19 Cohort.新冠疫情最初几个月的妊娠与分娩结局:MOACC - 19队列研究
Int J Environ Res Public Health. 2021 Oct 18;18(20):10931. doi: 10.3390/ijerph182010931.
5
Intranasal Immunization with the Influenza A Virus Encoding Truncated NS1 Protein Protects Mice from Heterologous Challenge by Restraining the Inflammatory Response in the Lungs.用编码截短型NS1蛋白的甲型流感病毒进行鼻内免疫可通过抑制肺部炎症反应保护小鼠免受异源攻击。
Microorganisms. 2021 Mar 26;9(4):690. doi: 10.3390/microorganisms9040690.
6
Characterization of Inactivated Influenza Vaccines Used in the Russian National Immunization Program.俄罗斯国家免疫规划中使用的灭活流感疫苗的特性
Vaccines (Basel). 2020 Aug 30;8(3):488. doi: 10.3390/vaccines8030488.
7
Targeting Hemagglutinin: Approaches for Broad Protection against the Influenza A Virus.针对血凝素:广泛预防甲型流感病毒的方法。
Viruses. 2019 Apr 30;11(5):405. doi: 10.3390/v11050405.
8
Passive inhalation of dry powder influenza vaccine formulations completely protects chickens against H5N1 lethal viral challenge.被动吸入干粉流感疫苗制剂可完全保护鸡免受 H5N1 致死性病毒挑战。
Eur J Pharm Biopharm. 2018 Dec;133:85-95. doi: 10.1016/j.ejpb.2018.10.008. Epub 2018 Oct 9.
Immunity. 2017 Oct 17;47(4):599-603. doi: 10.1016/j.immuni.2017.09.007.
4
A Broadly Reactive Human Anti-hemagglutinin Stem Monoclonal Antibody That Inhibits Influenza A Virus Particle Release.一种广谱反应性人抗血凝素茎单克隆抗体,可抑制甲型流感病毒粒子释放。
EBioMedicine. 2017 Mar;17:182-191. doi: 10.1016/j.ebiom.2017.03.007. Epub 2017 Mar 6.
5
Antibody-dependent cellular cytotoxicity and influenza virus.抗体依赖的细胞毒性作用与流感病毒
Curr Opin Virol. 2017 Feb;22:89-96. doi: 10.1016/j.coviro.2016.12.002. Epub 2017 Jan 11.
6
2014-2015 Influenza Vaccine Effectiveness in the United States by Vaccine Type.2014 - 2015年美国按疫苗类型划分的流感疫苗效力
Clin Infect Dis. 2016 Dec 15;63(12):1564-1573. doi: 10.1093/cid/ciw635. Epub 2016 Oct 4.
7
Modulation of the pH Stability of Influenza Virus Hemagglutinin: A Host Cell Adaptation Strategy.流感病毒血凝素pH稳定性的调节:一种宿主细胞适应策略。
Biophys J. 2016 Jun 7;110(11):2293-2301. doi: 10.1016/j.bpj.2016.04.035.
8
Broadly-Reactive Neutralizing and Non-neutralizing Antibodies Directed against the H7 Influenza Virus Hemagglutinin Reveal Divergent Mechanisms of Protection.针对H7流感病毒血凝素的广泛反应性中和及非中和抗体揭示了不同的保护机制。
PLoS Pathog. 2016 Apr 15;12(4):e1005578. doi: 10.1371/journal.ppat.1005578. eCollection 2016 Apr.
9
A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen.稳定的三聚体流感血凝素茎作为一种广泛保护性的免疫原。
Science. 2015 Sep 18;349(6254):1301-6. doi: 10.1126/science.aac7263. Epub 2015 Aug 24.
10
Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection.血凝素茎纳米颗粒产生异源型流感保护。
Nat Med. 2015 Sep;21(9):1065-70. doi: 10.1038/nm.3927. Epub 2015 Aug 24.